In August 2017 Mr. Avinash Seth filed an International and US Utility Patent (as the principal inventor) under the proprietorship of So Young Life Sciences Corporation for developing non-tumorigenic Induced Pluripotent Stem Cells with novel transcription factors. This patent details a technique of creating non-tumorigenic Induced Pluripotent Stem Cells (iPSC’s) from any somatic cell (body cell) without using viruses as the vector delivery mechanism for cellular reprogramming. The results of the patent elucidated a novel way of creating non-tumorigenic Induced Pluripotent Stem Cells thereby unlocking their true potential from a clinical standpoint in organogenesis and Regenerative Medicine. Through these robust and mutagenic free iPSC’s it is able to recapitulate the growth of any tissue and with proper Tissue Engineering techniques any organ could be resurrected. This Utility Patent was published in the WIPO (World Intellectual Property Organization) and US PCT (Patent Cooperation Treaty) database in October 2019.
In October 2018 Mr. Avinash Seth, Mr. Nikko Lowe and Mr. Robert Fish filed an International and US Utility Patent (as principal inventors) under the proprietorship of So Young Life Sciences Corporation, a technique for treating breast and pancreatic cancer cells using a tumor suppressor protein and a liposome (a nanosized gene delivery system) carrying the gene expressing the tumor suppressor protein.
This patent details the technique of treating highly aggressive human pancreatic and breast cancer cell lines using liposomes that contain a potent tumor suppressor protein and the gene that encodes the tumor suppressive protein. The results of the patent illustrated that the liposomes were capable of inducing greater than 95 percent cancer cell death of the aforementioned cancer cell lines and reduced their proliferation rate by 91 percent. These aggressive cancer cell lines were able to resist the conventional methods of treatment such as administration of chemotherapeutic agents, radiation and other anti-cancer molecules. This Utility Patent was published in the WIPO and US PCT database in October 2020.
In April 2019 So Young Life Sciences Corporation and the Indian Multi-Billion Dollar FMCG (Fast Moving Consumer Good) Conglomerate DS Group India Pvt Ltd. formed a joint venture to develop a smokeless tobacco product that would reduce the risk of smokeless tobacco consumers from developing lung and throat cancer. This project resulted in the creation of a parent independent company Gamot Global Pvt Ltd headquartered in Singapore which was jointly owned by both the companies as the proprietor of all Intellectual Properties which encompassed the area of developing smokeless tobacco products and other derivatives from a health care standpoint.
In May 2019 Mr. Avinash Seth, and Mr. Robert Fish filed an International and US Utility Patent (as principal inventors) under the proprietorship of Gamot Global Pvt Ltd which described compositions of different smokeless tobacco products and derivatives which reduced the negative effects of smokeless tobacco consumption. The patent details compositions and methods for creating various smokeless tobacco products that reduce the risk of tobacco consumption, in particular the risk of developing lung and throat cancer. The results of the patent indicate that these novel smokeless tobacco products and derivatives are able to suppress the growth of human lung cancer cells and throat cancer cell lines by ninety percent. In addition, the results also indicate that these smokeless tobacco products do not affect the growth of healthy human lung cells and tissue.